Tumor target motion is a significant factor in inhibiting increasing levels of accuracy. The development of X-ray volume imaging (XVI) and its suite of imaging tools was driven by the need to visualize internal structures within the reference frame of the treatment system in order to reduce geometric uncertainties. The ability to image at the point of treatment and in the treatment position reduces issues relating to organ movement and inspires clinical confidence to pursue IMRT delivery.
XVI was developed by Elekta in close collaboration with clinical partners, ensuring the features, functionality and efficiency meet the needs of all modern clinics. Working closely with the Elekta Synergy Research Group, Elekta became the first company to support research on IGRT, the first to bring 3D volumetric imaging into clinical use and the first to bring these solutions to the wider market.
XVI imaging technology
Planning and treating in 3D requires verification in 3D. The 3D imaging capability of XVI enables the clinician to take full advantage of complex technique dose delivery without the need for implanted target surrogate markers to visualize soft tissue structures, target volume and critical structure position. It allows precise registration of the reconstructed image data with the historical CT planning data as a non-invasive procedure. XVI offers a variety of image guided options to suit the individual needs of the patient and the clinic The XVI software offers the flexibility to vary the dosage necessary to acquire a VolumeView image, depending on the level of contrast required.
Key visualization advantages offered by VolumeView imaging at the time of treatment include:
- soft tissue size, shape and position
- critical organs and tumors
- bony anatomy and alignment in 3D
- eliminate the need for surrogate markers
- ability to minimize the imaging dose
- overlay of structures defined in treatment planning system
- large field-of-view
- simultaneous acquisition and reconstruction